Table 2.
Results of susceptibility testing for Gram-negative isolates (N=92*).
| Antimicrobials |
Klebsiella spp. (N=45), n (%) susceptible |
Enterobacter spp. (N=23), n (%) susceptible |
E.coli (N=11), n (%) susceptible |
Acinetobacter baumannii (N=7), n (%) susceptible |
Pseudomonas spp. (N=6), n (%) susceptible |
|---|---|---|---|---|---|
| Beta-lactam | |||||
| Ampicillin/ Sulbactam |
*** | *** | *** | 5 (71) | *** |
| Amoxicillin | 1 (2) | 1 (4) | 5 (45) | *** | *** |
| Amoxicillin clavulanate |
34 (76) | *** | 7 (64) | *** | *** |
| Ticarcillin/ Clavulanate |
37 (82) | 13 (57) | 8 (73) | 4 (57) | 5 (83) |
| Piperacillin/ Tazobactam |
38 (84) | 15 (65) | 10 (91) | 4 (57) | 5 (83) |
| Cefazolin | 34 (76) | *** | *** | *** | *** |
| Cefepime | 40 (89) | 19 (83) | 10 (91) | 4 (57) | 5 (83) |
| Cefotaxime | 38 (84) | 16 (70) | 10 (91) | 2 (29) | 5 (83) |
| Ceftazidime | 37 (82) | 15 (65) | 10 (91) | 4 (57) | 5 (83) |
| Ceftriaxone | 40 (89) | 15 (65) | 10 (91) | 2 (29) | 5 (83) |
| Imipenem | 44 (98) | 22 (96) | 10 (91) | 6 (86) | 5 (83) |
| Non-beta-lactam | |||||
| Amikacin | 44 (98) | 22 (96) | 10 (91) | 6 (86) | 4 (67) |
| Gentamicin | 40 (89) | 21 (91) | 9 (82) | *** | 2 (33) |
| Tobramycin | 43 (96) | 21 (91) | 10 (91) | 5 (71) | 3 (50) |
| Ciprofloxacin | 43 (96) | 22 (96) | 10 (91) | 5 (71) | 5 (83) |
| Moxifloxacin | 43 (96) | 22 (96) | 10 (91) | 5 (71) | 5 (83) |
| Tetracycline | 34 (76) | 16 (70) | 8 (73) | 4 (57) | *** |
| TMS-SMX | 22 (49) | 15 (65) | 7 (64) | 3 (43) | *** |
Note.
*
Susceptibilities for Acinetobacter iwoffi (N=2), Burkholderia cepacia (N=2), Serratia marcescens (N=1), Salmonella choleraesuis (N=1) were not tested because of small numbers of isolates.
***
not tested for susceptibility to this antibiotic/antimicrobial.
TMS-SMX - Trimethoprim sulfamethoxazole